Stock analysts at StockNews.com initiated coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) in a note issued to investors on Saturday. The firm set a “sell” rating on the stock.
Ampio Pharmaceuticals Trading Down 12.9 %
Shares of Ampio Pharmaceuticals stock opened at $0.62 on Friday. The firm’s 50 day moving average is $1.47 and its 200 day moving average is $2.10. The firm has a market capitalization of $706,800.00, a PE ratio of -0.06 and a beta of 1.95. Ampio Pharmaceuticals has a 1 year low of $0.62 and a 1 year high of $8.30.
Hedge Funds Weigh In On Ampio Pharmaceuticals
Several large investors have recently bought and sold shares of the company. Two Sigma Advisers LP raised its stake in shares of Ampio Pharmaceuticals by 304.3% during the third quarter. Two Sigma Advisers LP now owns 432,216 shares of the company’s stock valued at $26,000 after acquiring an additional 325,300 shares during the last quarter. HRT Financial LP raised its position in Ampio Pharmaceuticals by 1,399.2% during the 1st quarter. HRT Financial LP now owns 217,052 shares of the company’s stock worth $50,000 after purchasing an additional 202,574 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Ampio Pharmaceuticals by 73.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 394,100 shares of the company’s stock worth $66,000 after purchasing an additional 166,979 shares during the last quarter. Virtu Financial LLC acquired a new position in Ampio Pharmaceuticals during the 2nd quarter worth about $72,000. Finally, Bank of Montreal Can bought a new stake in shares of Ampio Pharmaceuticals in the 1st quarter valued at about $168,000. 5.73% of the stock is currently owned by institutional investors.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.
Further Reading
- Five stocks we like better than Ampio Pharmaceuticals
- Stock Dividend Cuts Happen Are You Ready?
- You Can Follow BlackRock’s Market View for Your Money
- 5 discounted opportunities for dividend growth investors
- Breakout Alert: Coinbase’s Consolidation Is About To End
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Key Stocks Helping to Drive the EV Race
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
